Cassava’s Simufilam Continues To Alienate Investors Despite Some Phase II Alzheimer’s Promise

 
• By Ayisha Sharma
  
Businessman walking on animated red arrow that is pointing diagonal and downwards
Simufilam's Efficacy Has Been Declining With Each Data Release • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapy Areas